Work

Pemetrexed with or without Matuzumab as Second-Line Treatment for Patients with Stage IIIB/IV Non-small Cell Lung Cancer

Year: 2010

Type: article

Study designs: Randomized Controlled Trial, Clinical Trial

Source: Journal of Thoracic Oncology

DOI: 10.1097/jto.0b013e3181f4a5c9

Authors: Joan H. Schiller, Joachim von Pawel, Philipp Schütt, Rafat H. Ansari, Michael Thomas, Mansoor Saleh, Robert D. McCroskey, Wolfgang Pfeifer, Thomas A. Marsland, Goetz H. Kloecker, Martin Sebastian, Robert Pirker, Raffael Kurek, Claire Beadman, Mark A. Socinski

Institutions: Harold C. Simmons Comprehensive Cancer Center, The University of Texas Southwestern Medical Center, Asklepios Fachkliniken München-Gauting, Essen University Hospital, Northern Indiana Cancer Research Consortium, Georgia Cancer Specialists, Johannes Gutenberg University Mainz, University Medical Center of the Johannes Gutenberg University Mainz, Medical University of Vienna, Merck KGaA, Darmstadt (Germany), University of North Carolina at Chapel Hill, UNC Lineberger Comprehensive Cancer Center

Language: English

Topic: Lung Cancer Treatments and Mutations

Subfield: Pulmonary and Respiratory Medicine

Field: Medicine

Domain: Health Sciences

SDG: Good health and well-being

Open Access status: bronze

Funder: Merck KGaA

OpenAlex ID: W2083150541

FWCI: 5.316

Cites: 35

Cited by: 51

Related to: 10